logo

Catabasis Pharmaceuticals, Inc. (CATB)



Trade CATB now with
  Date
  Headline
6/12/2020 8:04:13 AM Catabasis Names Ben Harshbarger As SVP, General Counsel
3/10/2020 8:09:08 AM Catabasis Pharma Q4 Net Loss $6.6 Mln Or $0.55/Shr Vs Loss Of $6.1 Mln Or $0.85/Shr Last Year
1/8/2020 8:12:59 AM Catabasis, Duchenne UK Partner To Evaluate Edasalonexent In Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
11/7/2019 8:10:38 AM Catabasis Pharmaceuticals Q3 Net Loss $6.5 Mln Or $0.56/Shr Vs Net Loss $5.7 Mln Or $0.80/Shr Prior Year
9/25/2019 8:05:54 AM Catabasis Pharmaceuticals Names Andrew Komjathy Chief Commercial Officer
7/29/2019 7:20:36 AM Wedbush Reiterates Catabasis Pharmaceuticals, Inc. (CATB) At Outperform With $18 Price Target
6/24/2019 10:03:28 AM Wedbush Reiterates Catabasis Pharmaceuticals, Inc. (CATB) At Outperform With $18 Price Target
5/14/2019 8:17:48 AM Catabasis Pharma Q1 Net Loss $6.0 Mln Or $0.62/Shr Vs Loss $7.7 Mln Or $2.88/Shr Last Year
3/14/2019 8:10:13 AM Catabasis Pharma Q4 Net Loss $6.1 Mln Or $0.85/Shr Vs Loss Of $5.5 Mln Or $2.37/Shr Last Year
2/14/2019 8:11:26 AM Catabasis Pharma Appoints Joanne Beck To Board Of Directors
2/6/2019 9:04:44 AM Catabasis Reports Pricing Of $20 Mln Public Offering
1/4/2019 8:08:45 AM Catabasis Pharmaceuticals Appoints Gregg Lapointe To Its Board
1/3/2019 8:25:48 AM Catabasis Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy Progress Update
12/24/2018 8:26:07 AM Catabasis Says Will Effect One-for-ten Reverse Stock Split Of Common Stock That Will Be Effective On December 28
11/27/2018 8:09:49 AM Catabasis Announces Publication Of Phase 1 Results Of Edasalonexent In Duchenne Muscular Dystrophy
11/13/2018 8:29:49 AM Catabasis Q3 Net Loss $5.7 Mln Or $0.08/shr Vs. Net Loss Of $7.0 Mln Or $0.31/shr Last Year
11/13/2018 7:50:22 AM Catabasis, UT Southwestern To Explore Benefits Of Edasalonexent On Cardiac Function In Duchenne, BMD